Cevipabulin-tubulin complex reveals a novel agent binding site on α-tubulin with tubulin degradation effect

Jianhong Yang, Yamei Yu, Yong Li, +16

Science Advances

Identification of Pyrrolo[2,3-<i>d</i>]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia

Xue Yuan, Yong Chen, Wanhua Zhang, +15

Journal of Medicinal Chemistry

Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i> –Induced B-Cell Acute Lymphoblastic Leukemia

Linyu Yang, Qiang Qiu, Minghai Tang, +17

Clinical Cancer Research

Identification of a Novel 2,8-Diazaspiro[4.5]decan-1-one Derivative as a Potent and Selective Dual TYK2/JAK1 Inhibitor for the Treatment of Inflammatory Bowel Disease

Tao Yang, Xue Cui, Minghai Tang, +10

Journal of Medicinal Chemistry

Discovery of a Series of Hydroxamic Acid-Based Microtubule Destabilizing Agents with Potent Antitumor Activity

Linyu Yang, Wanhua Zhang, Qiang Qiu, +14

Journal of Medicinal Chemistry

HDAC I/IIb selective inhibitor Purinostat Mesylate combined with GLS1 inhibition effectively eliminates CML stem cells

Qiang Qiu, Linyu Yang, Yunyu Feng, +16

Bioactive Materials

Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms

Mengshi Hu, Tao Yang, Linyu Yang, +13

Blood Cancer Journal

TSPAN32 suppresses chronic myeloid leukemia pathogenesis and progression by stabilizing PTEN

Qiang Qiu, Yuanyuan Sun, Linyu Yang, +16

Signal Transduction and Targeted Therapy

Molecular dynamics simulations of the conformational plasticity in the active pocket of salt-inducible kinase 2 (SIK2) multi-state binding with bosutinib

Mingsong Shi, Lun Wang, Kongjun Liu, +6

Computational and Structural Biotechnology Journal